SNFGE SNFGE
 
Thématique :
- Intestin/Nutrition/Troubles fonctionnels
Originalité :
Intermédiaire
Solidité :
Intermédiaire
Doit faire évoluer notre pratique :
Dans certains cas
 
 
Nom du veilleur :
Docteur Pauline JOUET
Coup de coeur :
 
 
Gastroenterology
  2016/08  
 
  2016 Aug;151(2):271-7  
  doi: 10.1053/j.gastro.2016.04.013  
 
  Risks of Bleeding Recurrence and Cardiovascular Events With Continued Aspirin Use After Lower Gastrointestinal Hemorrhage  
 
  Chan FK, Leung Ki EL, Wong GL, Ching JY, Tse YK, Au KW, Wu JC, Ng SC  
  https://www.ncbi.nlm.nih.gov/pubmed/27130815  
 
 

BACKGROUND & AIMS:

It is not clear whether use of low-dose aspirin should be resumed after an episode of lower gastrointestinal (GI) bleeding. We assessed the long-term risks of recurrent lower GI bleeding and serious cardiovascular outcomes after aspirin-associated lower GI bleeding.

METHODS:

We performed a retrospective study of patients diagnosed with lower GI bleeding (documented melena or hematochezia and absence of upper GI bleeding) from January 1, 2000 through December 31, 2007 at the Prince of Wales Hospital in Hong Kong. Using the hospital registry, we analyzed data from 295 patients on aspirin and determined their outcomes during a 5-year period. Outcomes included recurrent lower GI bleeding, serious cardiovascular events, and death from other causes, as determined by an independent, blinded adjudication committee. Outcomes were compared between patients assigned to the following groups based on cumulative duration of aspirin use: <20% of the follow-up period (121 nonusers) vs ≥50% of the observation period (174 aspirin users).

RESULTS:

Within 5 years, lower GI bleeding recurred in 18.9% of aspirin users (95% confidence interval [CI], 13.3%-25.3%) vs 6.9% of nonusers (95% CI, 3.2%-12.5%; P = .007). However, serious cardiovascular events occurred in 22.8% of aspirin users (95% CI, 16.6%-29.6%) vs 36.5% of nonusers (95% CI, 27.4%-45.6%; P = .017), and 8.2% of aspirin users died from other causes (95% CI, 4.6%-13.2%) vs 26.7% of nonusers (95% CI, 18.7%-35.4%; P = .001). Multivariable analysis showed that aspirin use was an independent predictor of rebleeding, but protected against cardiovascular events and death.

CONCLUSIONS:

Among aspirin users with a history of lower GI bleeding, continuation of aspirin is associated with an increased risk of recurrent lower GI bleeding, but reduced risk of serious cardiovascular events and death.

Copyright © 2016. Published by Elsevier Inc.

 
Question posée
 
Quels sont les risques de récidive de saignement d’origine digestive basse et/ou d’évènement cardiovasculaire sérieux chez les patients ayant repris l’aspirine après un épisode d’hémorragie digestive basse ?
 
Question posée
 
Dans cette étude rétrospective effectuée chez 295 patients après une hémorragie digestive basse sous aspirine, les patients qui reprenaient l’aspirine avaient un risque de récidive de saignement digestif bas près de trois fois plus élevé que ceux sans aspirine, mais avec une diminution du risque d’évènement cardiaque sérieux de 1,6 fois, et du risque de décès d’une autre cause de plus de trois fois.
 
Commentaires

Cette étude, bien que rétrospective et non randomisée, nous apporte des informations importantes sur les bénéfices/risques de l’arrêt de l’aspirine après un épisode d’hémorragie digestive basse.

 
www.snfge.org